NASDAQ:AMRS - Amyris Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.03 -0.15 (-2.90 %)
(As of 05/27/2018 06:10 AM ET)
Previous Close$5.03
Today's Range$4.8966 - $5.16
52-Week Range$1.86 - $7.30
Volume670,352 shs
Average Volume785,962 shs
Market Capitalization$252.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.15

About Amyris (NASDAQ:AMRS)

Amyris logoAmyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Debt-to-Equity Ratio-0.35
Current Ratio0.67
Quick Ratio0.93

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$143.45 million
Price / Sales1.76
Cash FlowN/A
Price / CashN/A
Book Value($5.80) per share
Price / Book-0.87

Profitability

EPS (Most Recent Fiscal Year)($3.05)
Net Income$-72,320,000.00
Net Margins-85.70%
Return on EquityN/A
Return on Assets-125.68%

Miscellaneous

Employees414
Outstanding Shares50,180,000

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($1.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $1.31. The biotechnology company earned $23 million during the quarter, compared to the consensus estimate of $24.12 million. The business's revenue was up 77.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) earnings per share. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

3 Wall Street analysts have issued 12 month target prices for Amyris' shares. Their forecasts range from $4.00 to $15.00. On average, they expect Amyris' share price to reach $9.6667 in the next year. View Analyst Ratings for Amyris.

Who are some of Amyris' key competitors?

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 57)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
  • Ms. Tina F. Maloney, Chief Accounting Officer (Age 55)

Has Amyris been receiving favorable news coverage?

Press coverage about AMRS stock has trended somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.04 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Amyris' major shareholders?

Amyris' stock is owned by many different of institutional and retail investors. Top institutional shareholders include TEMASEK HOLDINGS (PRIVATE) LTD (8.90%), Millennium Management LLC (0.49%), Crown Advisors Management Inc. (0.20%), JPMorgan Chase & Co. (0.20%), KBC Group NV (0.13%) and BlackRock Inc. (0.11%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, John Melo, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

Which major investors are buying Amyris stock?

AMRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Crown Advisors Management Inc., JPMorgan Chase & Co., Barclays PLC, Tibra Equities Europe Ltd, B. Riley Financial Inc., Element Capital Management LLC and BlackRock Inc.. Company insiders that have bought Amyris stock in the last two years include L John Doerr and Patrick Y Yang. View Insider Buying and Selling for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $5.03.

How big of a company is Amyris?

Amyris has a market capitalization of $252.39 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (AMRS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amyris (NASDAQ:AMRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Amyris in the last 12 months. Their average twelve-month price target is $9.6667, suggesting that the stock has a possible upside of 92.18%. The high price target for AMRS is $15.00 and the low price target for AMRS is $4.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.6667$9.6667$9.00$26.3333
Price Target Upside: 92.18% upside44.49% upside81.82% upside730.70% upside

Amyris (NASDAQ:AMRS) Consensus Price Target History

Price Target History for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ:AMRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2018HC WainwrightSet Price TargetBuy$15.00MediumView Rating Details
5/20/2018B. RileySet Price TargetBuy$10.00LowView Rating Details
11/29/2017CowenReiterated RatingHold$4.00HighView Rating Details
1/11/2017Rodman & RenshawReiterated RatingBuy$60.00N/AView Rating Details
9/28/2016Singular ResearchReiterated RatingBuy$42.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Amyris (NASDAQ:AMRS) Earnings History and Estimates Chart

Earnings by Quarter for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ:AMRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
2019 EPS Consensus Estimate: $0.16
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.38)($0.38)($0.38)
Q2 20181($0.30)($0.30)($0.30)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181$0.23$0.23$0.23
Q1 20191($0.13)($0.13)($0.13)
Q2 20191($0.03)($0.03)($0.03)
Q3 20191$0.06$0.06$0.06
Q4 20191$0.26$0.26$0.26

Amyris (NASDAQ AMRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.30)N/AView Earnings Details
5/14/2018Q1 2018($0.48)($1.79)$24.12 million$23.00 millionViewListenView Earnings Details
3/15/2018Q4 2017$0.07($0.17)$68.14 million$80.59 millionViewListenView Earnings Details
11/14/2017Q3 2017($0.77)($0.81)$36.30 million$24.20 millionViewN/AView Earnings Details
8/10/2017Q2 2017($1.06)($1.41)$23.68 million$25.68 millionViewN/AView Earnings Details
5/15/2017Q1 2017($1.35)($1.95)$32.30 million$13.00 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.75)($1.50)$38.72 million$32.20 millionViewListenView Earnings Details
11/2/2016Q316($0.90)($1.05)$33.61 million$26.50 millionViewN/AView Earnings Details
8/4/2016Q2($1.80)($0.90)$15.23 million$9.60 millionViewN/AView Earnings Details
5/10/2016Q1($1.95)($2.55)$10.39 million$8.80 millionViewListenView Earnings Details
3/9/2016Q4($1.50)($2.40)$32.44 million$9.80 millionViewListenView Earnings Details
11/5/2015Q315($2.55)($3.45)$8.84 million$8.60 millionViewN/AView Earnings Details
8/6/2015Q215($4.65)($7.95)$15.66 million$7.80 millionViewN/AView Earnings Details
5/5/2015Q115($1.50)($6.15)$21.40 million$7.90 millionViewN/AView Earnings Details
2/24/2015Q414($3.00)($12.60)$20.12 million$11.60 millionViewN/AView Earnings Details
11/4/2014Q314($2.10)($4.20)$20.51 million$16.34 millionViewN/AView Earnings Details
8/7/2014Q214($5.55)($5.25)$12.36 million$9.30 millionViewN/AView Earnings Details
5/8/2014Q114($4.80)($5.40)$13.50 million$17.90 millionViewN/AView Earnings Details
2/25/2014Q413($3.60)($3.90)$18.66 million$15.40 millionViewN/AView Earnings Details
10/31/2013Q313($4.50)($4.80)$13.59 million$7.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($4.80)($5.10)$11.47 million$10.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($5.85)($5.85)$9.80 million$7.87 millionViewN/AView Earnings Details
2/19/2013Q4 2012($7.65)($7.35)$10.68 million$5.90 millionViewN/AView Earnings Details
11/6/2012Q312($9.45)($3.30)$10.49 million$19.10 millionViewN/AView Earnings Details
7/31/2012($10.35)($9.90)ViewN/AView Earnings Details
5/8/2012($11.40)($28.20)ViewN/AView Earnings Details
2/27/2012Q4 2011($12.74)($19.51)ViewN/AView Earnings Details
11/1/2011($10.65)($14.55)ViewN/AView Earnings Details
8/2/2011($9.45)($14.25)ViewN/AView Earnings Details
5/5/2011($7.50)($11.40)ViewN/AView Earnings Details
2/28/2011($7.35)($7.65)ViewN/AView Earnings Details
11/4/2010Q3 2010($57.74)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amyris (NASDAQ:AMRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amyris (NASDAQ AMRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.80%
Institutional Ownership Percentage: 23.95%
Insider Trading History for Amyris (NASDAQ:AMRS)
Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Amyris (NASDAQ AMRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/7/2018(Mauritius) Pte Ltd MaxwellMajor ShareholderSell95,162$6.54$622,359.48View SEC Filing  
1/16/2018John MeloInsiderSell10,776$4.68$50,431.6883,172View SEC Filing  
5/19/2017Patrick Y YangDirectorBuy300,000$0.29$87,000.00153,000View SEC Filing  
4/20/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell652,513$0.55$358,882.15View SEC Filing  
4/18/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,636,930$0.65$1,064,004.50View SEC Filing  
3/30/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell184,535$0.51$94,112.85View SEC Filing  
3/29/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell417,990$0.51$213,174.90View SEC Filing  
3/27/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell129,059$0.48$61,948.32View SEC Filing  
3/23/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell165,428$0.48$79,405.44View SEC Filing  
3/21/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell223,073$0.48$107,075.04View SEC Filing  
3/20/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell88,382$0.49$43,307.18View SEC Filing  
3/17/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell339,908$0.49$166,554.92View SEC Filing  
3/15/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell270,374$0.46$124,372.04View SEC Filing  
3/13/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell346,429$0.50$173,214.50View SEC Filing  
3/9/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell520,925$0.46$239,625.50View SEC Filing  
3/7/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell852,224$0.45$383,500.80View SEC Filing  
3/3/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell868,589$0.49$425,608.61View SEC Filing  
3/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell377,823$0.51$192,689.73View SEC Filing  
2/27/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell287,706$0.52$149,607.12View SEC Filing  
2/23/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell529,747$0.53$280,765.91View SEC Filing  
2/21/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell287,528$0.56$161,015.68View SEC Filing  
2/16/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell390,918$0.54$211,095.72View SEC Filing  
2/10/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell429,198$0.51$218,890.98View SEC Filing  
2/8/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell288,765$0.50$144,382.50View SEC Filing  
1/12/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell29,502$0.81$23,896.62View SEC Filing  
1/11/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell451,806$0.81$365,962.86View SEC Filing  
1/9/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,072,847$0.81$869,006.07View SEC Filing  
12/14/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell87,291$0.80$69,832.80View SEC Filing  
12/12/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell54,286$0.80$43,428.80View SEC Filing  
12/8/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell285,623$0.81$231,354.63View SEC Filing  
12/6/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell578,550$0.81$468,625.50View SEC Filing  
12/2/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell556,296$0.84$467,288.64View SEC Filing  
11/22/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell77,383$0.80$61,906.40View SEC Filing  
11/17/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell509,779$0.81$412,920.99View SEC Filing  
11/15/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell648,342$0.81$525,157.02View SEC Filing  
11/11/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell427,904$0.81$346,602.24View SEC Filing  
11/8/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell333,811$0.82$273,725.02View SEC Filing  
11/4/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell2,611,233$0.89$2,323,997.37View SEC Filing  
10/17/2016(Mauritius) Pte Ltd MaxwellMajor ShareholderSell2,300,000$0.83$1,909,000.00View SEC Filing  
6/14/2016L John DoerrDirectorBuy200,577$1.04$208,600.0815,000View SEC Filing  
10/14/2015Energies Nouvelles Activ TotalDirectorSell80,052$2.36$188,922.7264,178,185View SEC Filing  
6/5/2015John MeloCEOSell61,276$2.00$122,552.00View SEC Filing  
5/12/2015John MeloCEOSell65,575$2.08$136,396.00View SEC Filing  
5/15/2014L John DoerrDirectorBuy172,186$3.02$520,001.729,000View SEC Filing  
5/24/2013John MeloCEOSell24,402$2.85$69,545.70View SEC Filing  
3/27/2013Thani Sheikh Abdullah Bin K AlDirectorBuy1,533,742$3.26$4,999,998.92View SEC Filing  
12/24/2012Thani Sheikh Abdullah Bin K AlDirectorBuy3,355,704$2.98$9,999,997.92View SEC Filing  
8/31/2012John MeloCEOSell668,730$3.70$2,474,301.00View SEC Filing  
8/31/2012L John DoerrDirectorBuy270,270$3.70$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amyris (NASDAQ AMRS) News Headlines

Source:
DateHeadline
Financial Analysis: Pacific Ethanol (PEIX) & Amyris (AMRS)Financial Analysis: Pacific Ethanol (PEIX) & Amyris (AMRS)
www.americanbankingnews.com - May 26 at 7:22 PM
Amyris (AMRS) Presents At 19th Annual B. Riley FBR Investor Conference - SlideshowAmyris (AMRS) Presents At 19th Annual B. Riley FBR Investor Conference - Slideshow
seekingalpha.com - May 25 at 5:53 PM
HC Wainwright Reiterates "$15.00" Price Target for Amyris (AMRS)HC Wainwright Reiterates "$15.00" Price Target for Amyris (AMRS)
www.americanbankingnews.com - May 25 at 4:08 PM
 Brokerages Anticipate Amyris Inc (AMRS) Will Post Quarterly Sales of $37.53 Million Brokerages Anticipate Amyris Inc (AMRS) Will Post Quarterly Sales of $37.53 Million
www.americanbankingnews.com - May 24 at 8:59 AM
BRIEF-Temasek Holdings Reports 8.9 Pct Stake In Amyris IncBRIEF-Temasek Holdings Reports 8.9 Pct Stake In Amyris Inc
www.reuters.com - May 23 at 5:35 PM
Blog Exposure - Novvi and Chevron Sign Agreement to Develop and Bring to Market New Renewable Base Oil TechnologiesBlog Exposure - Novvi and Chevron Sign Agreement to Develop and Bring to Market New Renewable Base Oil Technologies
finance.yahoo.com - May 22 at 8:19 AM
-$0.30 EPS Expected for Amyris Inc (AMRS) This Quarter-$0.30 EPS Expected for Amyris Inc (AMRS) This Quarter
www.americanbankingnews.com - May 22 at 1:16 AM
BioDisrupt, Amyris Annual Investor Conference Provides Close-up of Technology & StrategyBioDisrupt, Amyris Annual Investor Conference Provides Close-up of Technology & Strategy
finance.yahoo.com - May 21 at 5:10 PM
Amyris (AMRS) Given a $10.00 Price Target at B. RileyAmyris (AMRS) Given a $10.00 Price Target at B. Riley
www.americanbankingnews.com - May 21 at 11:05 AM
Critical Survey: Methanex (MEOH) versus Amyris Biotechnologies (AMRS)Critical Survey: Methanex (MEOH) versus Amyris Biotechnologies (AMRS)
www.americanbankingnews.com - May 19 at 1:35 PM
Analyzing Pacific Ethanol (PEIX) and Amyris Biotechnologies (AMRS)Analyzing Pacific Ethanol (PEIX) and Amyris Biotechnologies (AMRS)
www.americanbankingnews.com - May 18 at 11:03 AM
Amyris Sustainable Lubricants Joint Venture Company, Novvi, and Chevron Enter Agreement To Develop and Bring To Market New Renewable Base Oil TechnologiesAmyris Sustainable Lubricants Joint Venture Company, Novvi, and Chevron Enter Agreement To Develop and Bring To Market New Renewable Base Oil Technologies
finance.yahoo.com - May 18 at 8:39 AM
B. Riley Equities Analysts Lower Earnings Estimates for Amyris Biotechnologies (AMRS)B. Riley Equities Analysts Lower Earnings Estimates for Amyris Biotechnologies (AMRS)
www.americanbankingnews.com - May 18 at 8:14 AM
Amyris Biotechnologies (AMRS) to Post Q4 2018 Earnings of $0.23 Per Share, B. Riley ForecastsAmyris Biotechnologies (AMRS) to Post Q4 2018 Earnings of $0.23 Per Share, B. Riley Forecasts
www.americanbankingnews.com - May 17 at 8:21 AM
Comparing Gevo (GEVO) and Amyris Biotechnologies (AMRS)Comparing Gevo (GEVO) and Amyris Biotechnologies (AMRS)
www.americanbankingnews.com - May 15 at 9:07 PM
Amyris Biotechnologies (AMRS) Given a $15.00 Price Target by HC Wainwright AnalystsAmyris Biotechnologies (AMRS) Given a $15.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 15 at 2:25 PM
Amyris Biotechnologies (AMRS) Posts  Earnings Results, Misses Expectations By $1.31 EPSAmyris Biotechnologies (AMRS) Posts Earnings Results, Misses Expectations By $1.31 EPS
www.americanbankingnews.com - May 15 at 8:28 AM
Edited Transcript of AMRS earnings conference call or presentation 14-May-18 8:30pm GMTEdited Transcript of AMRS earnings conference call or presentation 14-May-18 8:30pm GMT
finance.yahoo.com - May 15 at 8:26 AM
Amyris Continues Strong Momentum and Execution with 77% Revenue Growth and Exceeds Gross Margin TargetAmyris Continues Strong Momentum and Execution with 77% Revenue Growth and Exceeds Gross Margin Target
finance.yahoo.com - May 14 at 5:21 PM
Amyris Biotechnologies (AMRS) Receives Consensus Recommendation of "Buy" from AnalystsAmyris Biotechnologies (AMRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 12 at 1:15 AM
Amyris Biotechnologies (AMRS) Downgraded to Buy at BidaskClubAmyris Biotechnologies (AMRS) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - May 11 at 9:16 PM
Contrasting Amyris Biotechnologies (AMRS) and Methanex (MEOH)Contrasting Amyris Biotechnologies (AMRS) and Methanex (MEOH)
www.americanbankingnews.com - May 11 at 7:35 PM
Amyris to Participate in Upcoming Investor ConferencesAmyris to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 10 at 5:57 PM
Investors Buy High Volume of Call Options on Amyris Biotechnologies (AMRS)Investors Buy High Volume of Call Options on Amyris Biotechnologies (AMRS)
www.americanbankingnews.com - May 10 at 7:36 AM
Amyris Presents Its No Compromise™ Product Portfolio at Techonomy New YorkAmyris Presents Its No Compromise™ Product Portfolio at Techonomy New York
finance.yahoo.com - May 9 at 5:34 PM
Insider Selling: Amyris Biotechnologies (AMRS) Major Shareholder Sells 95,162 Shares of StockInsider Selling: Amyris Biotechnologies (AMRS) Major Shareholder Sells 95,162 Shares of Stock
www.americanbankingnews.com - May 9 at 10:12 AM
Future Outlook Of The Energy Industry And Amyris Inc (NASDAQ:AMRS)Future Outlook Of The Energy Industry And Amyris Inc (NASDAQ:AMRS)
finance.yahoo.com - May 8 at 5:39 PM
This Biotech Stock is Up 80% in 2018, but Is Its Business Model Sound?This Biotech Stock is Up 80% in 2018, but Is Its Business Model Sound?
finance.yahoo.com - May 8 at 8:16 AM
Amyris Biotechnologies (AMRS) Upgraded to "Buy" by ValuEngineAmyris Biotechnologies (AMRS) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - May 7 at 11:10 PM
Amyris Biotechnologies (AMRS) to Release Earnings on MondayAmyris Biotechnologies (AMRS) to Release Earnings on Monday
www.americanbankingnews.com - May 7 at 3:46 AM
 Analysts Anticipate Amyris Biotechnologies (AMRS) Will Announce Quarterly Sales of $24.12 Million Analysts Anticipate Amyris Biotechnologies (AMRS) Will Announce Quarterly Sales of $24.12 Million
www.americanbankingnews.com - May 6 at 2:40 AM
Amyris Biotechnologies (AMRS) Stock Rating Upgraded by BidaskClubAmyris Biotechnologies (AMRS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 5 at 1:06 AM
Amyris Collaborates with Firmenich to Develop Disruptive Bio-Based Fragrance IngredientAmyris Collaborates with Firmenich to Develop Disruptive Bio-Based Fragrance Ingredient
finance.yahoo.com - May 3 at 5:25 PM
Amyris Biotechnologies (AMRS) Cut to "Hold" at Zacks Investment ResearchAmyris Biotechnologies (AMRS) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 3 at 4:24 PM
Amyris Biotechnologies (AMRS) Rating Increased to Buy at Zacks Investment ResearchAmyris Biotechnologies (AMRS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 2 at 4:52 PM
Amyris Biotechnologies (AMRS) & Its Rivals Critical ContrastAmyris Biotechnologies (AMRS) & Its Rivals Critical Contrast
www.americanbankingnews.com - May 1 at 8:48 AM
Comparing Amyris Biotechnologies (AMRS) & The CompetitionComparing Amyris Biotechnologies (AMRS) & The Competition
www.americanbankingnews.com - April 30 at 3:20 AM
Amyris Biotechnologies (AMRS) and The Competition Head to Head SurveyAmyris Biotechnologies (AMRS) and The Competition Head to Head Survey
www.americanbankingnews.com - April 28 at 9:16 PM
Head-To-Head Contrast: Amyris Biotechnologies (AMRS) and Its PeersHead-To-Head Contrast: Amyris Biotechnologies (AMRS) and Its Peers
www.americanbankingnews.com - April 28 at 9:25 AM
Comparing Amyris Biotechnologies (AMRS) and Its RivalsComparing Amyris Biotechnologies (AMRS) and Its Rivals
www.americanbankingnews.com - April 27 at 5:20 PM
Amyris Biotechnologies (AMRS) Stock Rating Lowered by Zacks Investment ResearchAmyris Biotechnologies (AMRS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 26 at 4:22 PM
Amyris Biotechnologies (AMRS) & Its Competitors Head-To-Head AnalysisAmyris Biotechnologies (AMRS) & Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - April 26 at 3:13 PM
Amyris Biotechnologies (AMRS) Raised to "Buy" at Zacks Investment ResearchAmyris Biotechnologies (AMRS) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 4:04 PM
Head to Head Review: Amyris Biotechnologies (AMRS) & Its RivalsHead to Head Review: Amyris Biotechnologies (AMRS) & Its Rivals
www.americanbankingnews.com - April 24 at 11:18 AM
Critical Contrast: Amyris Biotechnologies (AMRS) vs. The CompetitionCritical Contrast: Amyris Biotechnologies (AMRS) vs. The Competition
www.americanbankingnews.com - April 24 at 9:22 AM
Amyris sees a future beyond fuelsAmyris sees a future beyond fuels
www.bizjournals.com - April 20 at 8:23 AM
 Analysts Expect Amyris Inc (AMRS) Will Post Quarterly Sales of $24.12 Million Analysts Expect Amyris Inc (AMRS) Will Post Quarterly Sales of $24.12 Million
www.americanbankingnews.com - April 19 at 2:50 AM
Amyris (AMRS) vs. Its Peers Financial ContrastAmyris (AMRS) vs. Its Peers Financial Contrast
www.americanbankingnews.com - April 18 at 9:14 PM
Reviewing Amyris (AMRS) and Its PeersReviewing Amyris (AMRS) and Its Peers
www.americanbankingnews.com - April 18 at 9:31 AM
Stock Review for Specialty Chemicals Investors -- Aemetis, Amyris, Axalta Coating Systems, and Delta TechnologyStock Review for Specialty Chemicals Investors -- Aemetis, Amyris, Axalta Coating Systems, and Delta Technology
www.prnewswire.com - April 18 at 8:16 AM

SEC Filings

Amyris (NASDAQ:AMRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amyris (NASDAQ:AMRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amyris (NASDAQ AMRS) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.